journal article·2022

Can two-step ablation combined with chemotherapeutic liposomes achieve better outcome than traditional RF ablation? A solid tumor animal study

Kun Zhao, Hao Wu, Wei Yang, Yuxi Cheng, Song Wang, An-na Jiang, Kun Yan, S Nahum Goldberg

Nanoscale· Volume 14· Issue 17
Publisher page

Abstract

Objectives: To determine whether two-step ablation using sequential low and high temperature heating can achieve improved outcomes in animal tumor models when combined with chemotherapeutic liposomes (LP). Materials and methods: Balb/c mice bearing 4T1 tumor received paclitaxel-loaded liposomes followed 24 h later by either traditional RFA (70 °C, 5 min) or a low temperature RFA (45 °C, 5 min), or two-step RFA (45 °C 2 min + 70 °C 3 min). Intratumoral drug accumulation and bio-distribution in major organs were evaluated. Periablational drug penetration was evaluated by pathologic staining and the intratumoral interstitial fluid pressure (IFP) was measured directly. For long-term outcomes, mice bearing 4T1 or H22 tumors were randomized into five groups (n = 8 per group): control (no treatment), RFA alone, LP + RFA (45 °C), LP + RFA (70 °C) and LP + RFA (45 + 70 °C). End-point survivals were compared among the different groups. Results: The greater intratumoral drug accumulation (3.35 ± 0.32 vs. 3.79 ± 0.29 × 108 phot/cm2/s at 24 h, p = 0.09), deeper periablational drug penetration (45.7 ± 5.0 vs. 1.6 ± 0.5, p < 0.001), and reduced off-target drug deposition in major organs (liver 96.1 ± 31.6 vs. 47.4 ± 1.5 × 106 phot/cm2/s, p < 0.001) were found when combined with RFA (45 °C) compared to drug alone. For long-term outcomes, 4T1 tumor growth rates for LP + two-step RFA (45 + 70 °C) were significantly slower than those of LP + RFA (70 °C), LP + RFA (45 °C), and RFA alone (P < 0.01 for all comparisons). End point survival for LP + RFA (45 + 70 °C) was also longer than that for LP + RFA (70 °C) (median 16 vs. 10 days, p = 0.003) or LP + RFA 45 °C (11 days, p = 0.009) and RFA alone (8.3 days, p < 0.001) in 4T1 tumor models. The intratumoral IFP after RFA (45 °C) was significantly lower than baseline RFA (3.3 ± 0.8 vs. 19.2 ± 3.1 mmHg, p < 0.001), but was not measurable after RFA (70 °C). Conclusions: A two-step ablation combined with chemotherapeutic liposomes can achieve better survival benefit compared to traditional RFA in animal models.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Radiation Therapy and Dosimetry · Ultrasound and Hyperthermia Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Ultrasound, Peking University Cancer Hospital & Institute, Beijing 100142, China

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Division of Image-guided Therapy, Department of Radiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel

Funding

National Natural Science Foundation of China

References (43)

Show source-provided references
1. Ahmed · Radiology · 2014 · 273 · 24110.1148/radiol.14132958 ↗
2. Feng · J. Hepatol. · 2012 · 57 · 79410.1016/j.jhep.2012.05.007 ↗
3. Chen · Ann. Surg. · 2006 · 243 · 32110.1097/01.sla.0000201480.65519.b8 ↗
4. Wu · Front. Oncol. · 2020 · 10
5. Sofocleous · Radiology · 2008 · 249 · 36410.1148/radiol.2491071752 ↗
6. Ni · World J. Gastroenterol. · 2013 · 19 · 387210.3748/wjg.v19.i24.3872 ↗
7. D'Ippolito · Radiology · 2003 · 228 · 11210.1148/radiol.2281020358 ↗
8. Ahmed · Radiology · 2005 · 235 · 46910.1148/radiol.2352031856 ↗
9. Wang · Radiology · 2016 · 150787
10. Yang · Radiology · 2010 · 257 · 68510.1148/radiol.10100500 ↗
11. Yan · Radiology · 2017 · 162405
12. Tak · Clin. Cancer Res. · 2018 · 24 · 7310.1158/1078-0432.CCR-16-2433 ↗
13. He · Acc. Chem. Res. · 2019 · 52 · 244510.1021/acs.accounts.9b00228 ↗
14. Wei · Nat. Mater. · 2020 · 19 · 48110.1038/s41563-020-0628-5 ↗
15. Sindhwani · Nat. Mater. · 2020 · 19 · 56610.1038/s41563-019-0566-2 ↗
16. Danhier · J. Controlled Release · 2016 · 244 · 10810.1016/j.jconrel.2016.11.015 ↗
17. Heldin · Nat. Rev. Cancer · 2004 · 4 · 80610.1038/nrc1456 ↗
18. Nichols · J. Controlled Release · 2014 · 190 · 45110.1016/j.jconrel.2014.03.057 ↗
19. Wu · Eur. Radiol. · 2019 · 29 · 620210.1007/s00330-019-06207-7 ↗
20. Goldberg · Radiology · 2001 · 220 · 42010.1148/radiology.220.2.r01au44420 ↗
21. Liao · Radiology · 2020 · 294 · 46410.1148/radiol.2019191023 ↗
22. Zhao · Biomaterials · 2014 · 35 · 603710.1016/j.biomaterials.2014.04.019 ↗
23. Al-Ahmady · J. Controlled Release · 2014 · 196 · 33210.1016/j.jconrel.2014.10.013 ↗
24. Zhang · Front. Pharmacol. · 2019 · 10 · 71610.3389/fphar.2019.00716 ↗
25. Lee · J. Controlled Release · 2017 · 263 · 6810.1016/j.jconrel.2017.02.035 ↗
26. Jain · Nat. Rev. Clin. Oncol. · 2010 · 7 · 65310.1038/nrclinonc.2010.139 ↗
27. Song · Clin. Cancer Res. · 2014 · 20 · 608310.1158/1078-0432.CCR-14-0493 ↗
28. Maruyama · Adv. Drug Delivery Rev. · 2011 · 63 · 16110.1016/j.addr.2010.09.003 ↗
29. Ma · ACS Nano · 2020 · 14 · 1590410.1021/acsnano.0c07287 ↗
30. Gabriele · Int. J. Hyperthermia · 2009 · 25 · 18910.1080/02656730802669593 ↗
31. Lu · Biomaterials · 2017 · 126 · 3910.1016/j.biomaterials.2017.02.025 ↗
32. Wang · Nanotheranostics · 2017 · 1 · 20810.7150/ntno.18767 ↗
33. Wang · Clin. Exp. Pharmacol. Physiol. · 2006 · 33 · 6610.1111/j.1440-1681.2006.04325.x ↗
34. Lee · Europace · 2001 · 3 · 19510.1053/eupc.2001.0167 ↗
35. Hapke · Cancer Lett. · 2020 · 487 · 1010.1016/j.canlet.2020.05.012 ↗
36. Najafi · J. Cancer Res. Clin. Oncol. · 2020 · 146 · 1910.1007/s00432-019-03080-1 ↗
37. Jacobsson · Mol. Oncol. · 2019 · 13 · 169310.1002/1878-0261.12500 ↗
38. Su · Curr. Drug Delivery · 2018 · 15 · 58510.2174/1567201814666170719111653 ↗
39. Tagami · J. Controlled Release · 2011 · 154 · 29010.1016/j.jconrel.2011.05.020 ↗
40. Regenold · Nanomedicine · 2021 · 40 · 10248410.1016/j.nano.2021.102484 ↗
41. Kruskal · J. Vasc. Interv. Radiol. · 2001 · 12 · 119310.1016/S1051-0443(07)61679-0 ↗
42. Andrasina · Cardiovasc. Intervent. Radiol. · 2019 · 42 · 75110.1007/s00270-019-02175-z ↗
43. Goins · Expert Opin. Drug Delivery · 2016 · 13 · 87310.1517/17425247.2016.1167035 ↗